COPD clinical trials in Louisiana
10 studies for COPD are looking for participants at sites in Louisiana.
Cities in Louisiana
A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)
- GSK Investigational Site, Lake Charles
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Nov 12, 2026 · NCT07780669To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment
- Care Access Research - Shreveport, Shreveport
RecruitingPhase 2
Ages 40 to 85 · All sexes · Updated Oct 28, 2026 · NCT07684820A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
- Research Site, Zachary
RecruitingPhase 2
Ages 40 and older · All sexes · Updated Oct 23, 2026 · NCT07082738Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
- Ochsner LSU Health Shreveport - Academic Medical Center- Site Number : 8400083, Shreveport
- Care Access - Shreveport - Youree Drive- Site Number : 8400007, Shreveport
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Oct 23, 2026 · NCT07190222A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
- Southern Clinical Research, LLC, Zachary
RecruitingPhase 2/3
Ages 35 to 80 · All sexes · Updated Oct 22, 2026 · NCT07363694Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
- Southern Clinical Research - Zachary- Site Number : 8400113, Zachary
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Oct 19, 2026 · NCT07190209STRIVE Post-Market Registry Study
- LSU Health Shreveport, Shreveport
RecruitingObservational study
Ages 18 and older · All sexes · Updated Oct 16, 2026 · NCT04302272Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
- GSK Investigational Site, Baton Rouge
- GSK Investigational Site, Lafayette
- GSK Investigational Site, Shreveport
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Oct 5, 2026 · NCT06961214A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
- Research Site, Lafayette
- Research Site, Monroe
- Research Site, Shreveport
- and 1 more
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Oct 2, 2026 · NCT06283966eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
- GSK Investigational Site, Lake Charles
- GSK Investigational Site, Shreveport
RecruitingPhase 3
Ages 40 to 75 · All sexes · Updated Jul 28, 2026 · NCT07177339From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.